Natera Inc.
Natera Reports Strong Q4 and Full Year 2024 Financial Results with Significant Revenue Growth
Summary
Natera, Inc. reported a robust financial performance for Q4 and the full year of 2024, with total revenues of $476.1 million for Q4 2024, a 53.0% increase from Q4 2023. Full-year revenues for 2024 were $1,696.9 million, a 56.7% increase from 2023. The company processed approximately 792,800 tests in Q4 2024, a 26.5% increase from Q4 2023. Natera generated a gross margin of 62.9% in Q4 2024 and 60.3% for the full year 2024. The company expects 2025 total revenue to be between $1.87 billion and $1.95 billion.
Profitelligence Alerts
Get alerts for NTRA
Be first to know when Natera Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Natera Inc.
Natera Inc., a leading player in the life sciences and diagnostics industry, specializes in developing cell-free DNA testing technologies. This biotechnological firm primarily focuses on non-invasive genetic testing, assisting in maternal-fetal medicine through the screening of high-risk pregnancies with its flagship product, Panorama. In addition to prenatal screening, Natera offers genetic solutions for oncology and organ health, providing critical insights through its comprehensive suite of products. These offerings are especially significant in cancer diagnostics, where Natera's technology helps in early detection, monitoring, and guiding treatment options. The company's innovative approach to DNA analysis enables the identification of genetic conditions and the monitoring of health trends with precision and ease, impacting healthcare providers, patients, and researchers. With its headquarters in San Carlos, California, Natera Inc. is at the forefront of genetic testing advancements, playing a pivotal role in personalizing medicine and revolutionizing patient care by enhancing early diagnosis capabilities and improving clinical outcomes.
Official SEC Documents
Advertisement